These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 29282685)

  • 1. Key Factors in Breast Cancer Dissemination and Establishment at the Bone: Past, Present and Future Perspectives.
    Owen S; Zabkiewicz C; Ye L; Sanders AJ; Gong C; Jiang WG
    Adv Exp Med Biol; 2017; 1026():197-216. PubMed ID: 29282685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
    Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
    Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657).
    Vidula N; Yau C; Li J; Esserman LJ; Rugo HS
    Breast Cancer Res Treat; 2017 Aug; 165(1):129-138. PubMed ID: 28577080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Examination of the mechanisms of osteolysis in patients with metastatic breast cancer.
    Trinkaus M; Ooi WS; Amir E; Popovic S; Kalina M; Kahn H; Singh G; Gainford MC; Clemons M
    Oncol Rep; 2009 May; 21(5):1153-9. PubMed ID: 19360288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases.
    Milone F; Pivonello C; Cariati F; Sarnataro M; Ramundo V; Marotta V; Jann H; Pape UF; Wiedenmann B; Colao A; Pavel M; Faggiano A
    Biomarkers; 2013 Mar; 18(2):121-5. PubMed ID: 23336103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis.
    Chanda D; Isayeva T; Kumar S; Siegal GP; Szafran AA; Zinn KR; Reddy VV; Ponnazhagan S
    Mol Ther; 2008 May; 16(5):871-8. PubMed ID: 18388919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
    Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
    Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer.
    Rachner TD; Kasimir-Bauer S; Göbel A; Erdmann K; Hoffmann O; Browne A; Wimberger P; Rauner M; Hofbauer LC; Kimmig R; Bittner AK
    Clin Cancer Res; 2019 Feb; 25(4):1369-1378. PubMed ID: 30425091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
    Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
    J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer.
    Sänger N; Ruckhäberle E; Bianchini G; Heinrich T; Milde-Langosch K; Müller V; Rody A; Solomayer EF; Fehm T; Holtrich U; Becker S; Karn T
    Mol Oncol; 2014 Oct; 8(7):1196-207. PubMed ID: 24785095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
    Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
    J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of osteoprotegrin and receptor activator of nuclear factor κB in breast cancer response to hepatocyte growth factor and the bone microenvironment in vitro.
    Owen S; Sanders AJ; Mason MD; Jiang WG
    Int J Oncol; 2016 Mar; 48(3):919-28. PubMed ID: 26781475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.
    Wittrant Y; Théoleyre S; Chipoy C; Padrines M; Blanchard F; Heymann D; Rédini F
    Biochim Biophys Acta; 2004 Sep; 1704(2):49-57. PubMed ID: 15363860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The RANK Pathway in Advanced Breast Cancer: Does Src Play a Role?
    Li R; Zhang K; Penedo TL; Kragel CP; Grizzle WE; Hameed O; Siegal GP; Wei S
    Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):42-50. PubMed ID: 26200837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases.
    Ferreira A; Alho I; Vendrell I; Melo M; Brás R; Costa AL; Sousa AR; Mansinho A; Abreu C; Pulido C; Macedo D; Pacheco T; Correia L; Costa L; Casimiro S
    Oncotarget; 2016 Jul; 7(27):41380-41389. PubMed ID: 27191503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
    Schubert A; Schulz H; Emons G; Gründker C
    Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy.
    Azim HA; Peccatori FA; Brohée S; Branstetter D; Loi S; Viale G; Piccart M; Dougall WC; Pruneri G; Sotiriou C
    Breast Cancer Res; 2015 Feb; 17():24. PubMed ID: 25849336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inhibitory acting mechanism of psoralen-osthole on bone metastasis of breast cancer--an expatiation viewing from OPG/RANKL/RANK system].
    Sheng L; Wu CY; Chen XF
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 May; 31(5):684-9. PubMed ID: 21812275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RANK-RANKL signalling in cancer.
    Renema N; Navet B; Heymann MF; Lezot F; Heymann D
    Biosci Rep; 2016 Aug; 36(4):. PubMed ID: 27279652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications].
    Clézardin P
    Bull Cancer; 2011 Jul; 98(7):837-46. PubMed ID: 21700551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.